OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
SOUTH SAN FRANCISCO, Calif., May 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 8th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2018.
The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (international) and entering passcode 9676198.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: | ||
| Maeve Conneighton | Willie Quinn | |
| Argot Partners | Sunesis Pharmaceuticals Inc. | |
| 212-600-1902 | 650-266-3716 | |
